BMCC-2022-PL03

Integrated Continuous Bioprocessing Platform

BMCC

Integrated Continuous Bioprocessing Platform

未定中標題
BMCC Targeted indication

1. High cell density perfusion culture.
2. Continuous chromatography for downstream processing.
3. In extreme favor of monitoring or improving quality and quantity.
4. Higher productivity and cost-saving than the traditional fed-batch manufacturing process.

BMCC Status

BMCC Key features
  • DCB has established an integrated continuous biomanufacturing system connecting the module of high cell-density perfusion culture to the continuous chromatography system; the VCD of perfusion culture is 50 ~ 80 x 106 cells/ml and produce antibody of about 2.0~3.0 g/L/day within 6 weeks.
BMCC Market
  • Constant of quality and quantity.
  • Higher productivity and cost-reduction

MODE OF ACTION